Document Type
EditorialPublication Date
2021-03-24Keywords
BiochemistryChemicals and Drugs
Medicinal Chemistry and Pharmaceutics
Medicinal-Pharmaceutical Chemistry
Pharmacy and Pharmaceutical Sciences
Metadata
Show full item recordAbstract
The evolutionary pressure of survival drives the emergence of drug resistance and thereby poses a major challenge to modern medicine. Resistance threatens the longevity of drugs and restricts treatment options for patients, with high prevalence in all areas of oncology and infectious diseases. Any biological entity capable of evolving and creating diversity can develop resistance under selective pressure. This diversity can pre-exist or occur after exposure to the inhibitors. Pathogens evolve to resist antimicrobials, which include antibiotics, antivirals, antifungals, and antiprotozoals. In agriculture, resistance arises with overuse of herbicides and pesticides. In cancer, resistance emerges eventually with most treatment regimens and in infectious diseases with spread of the pathogen to large populations, which is further exacerbated with the overuse of antibiotics. The emergence and spread of drug resistance in this wide range of disease areas severely impact public health, threaten millions of people’s lives, and cause a crippling financial burden, which urges the development of new strategies to unravel and avoid drug resistance.Source
Kurt Yilmaz N, Schiffer CA. Introduction: Drug Resistance. Chem Rev. 2021 Mar 24;121(6):3235-3237. doi: 10.1021/acs.chemrev.1c00118. PMID: 33757288; PMCID: PMC8164520. Link to article on publisher's site
DOI
10.1021/acs.chemrev.1c00118Permanent Link to this Item
http://hdl.handle.net/20.500.14038/29785PubMed ID
33757288Related Resources
ae974a485f413a2113503eed53cd6c53
10.1021/acs.chemrev.1c00118